Drugs / ECAR01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07052565 | Jul 2025 → Nov 2028 expected | autoimmune disease | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| — | NCT06961669 | Apr 2025 → Aug 2028 expected | acute lymphoblastic leukemia, refractory plasma cell neoplasm | Anhui Provincial Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECAR01 | “An Early Exploratory Clinical Study of Enhanced Autologous CAR-T Cell Injection (ECAR01) Targeting CD19 and BCMA in Patients With Relapsed or Refractory Multiple Myeloma, Acute...” NCT06961669 ↗1“An Exploratory Clinical Study of Enhanced Autologous CAR-T Cell Injection (ECAR01) Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases” NCT07052565 ↗ |
| Modality | Cell therapy | “Anti-BCMA and CD19 CART cells” NCT06961669 ↗ |
| Route | Intravenous | “injected intravenously” NCT06961669 ↗ |